摘要
非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是慢性肝病的主要病因,以肝脏代谢紊乱为主要改变,体现为脂质异常蓄积、肝细胞氧化应激等,其病因尚不明确.“肠肝轴”中法尼醇X受体(farnesoid X receptor,FXR)是一种主要的胆汁酸受体,在“肠-肝轴”的基础上,通过不同通路调节体内多种物质代谢和病理生理状态,进而影响NAFLD的发生发展,是一个具有潜力的治疗靶点.本文主要对FXR通过“肠-肝轴”调控体内胆汁酸与糖脂代谢进而改善NAFLD的机制进行综述,以为后续关于FXR靶点药物的研究提供思路.
Nonalcoholic fatty liver disease(NAFLD)is the main cause of chronic liver disease,with liver metabolic disorders as major pathological changes,manifested as abnormal lipid accumulation,liver cell oxidative stress,etc.,but its etiology is still unclear.The farnesol X receptor(FXR)is a major bile acid receptor in the“gut-liver axis”,via which FXR regulates metabolism and affects the pathophysiological status of various substances through different pathways,thus contributing to the occurrence and development of NAFLD.Therefore,FXR has become a potential therapeutic target for NAFLD.This article reviews the relationship between FXR regulation of bile acid,glucose,and lipid metabolism through the“gut-liver axis”and the occurrence and development of NAFLD,to provide new insights and clues for further research about FXR-based pharmaceutical treatments.
作者
黄之
周蓉蓉
Zhi Huang;Rong-Rong Zhou(Department of Infectious Diseases,Xiangya Hospital,Central South University,Changsha 410000,Hunan Province,China)
出处
《世界华人消化杂志》
CAS
2023年第19期797-807,共11页
World Chinese Journal of Digestology
基金
自然科学基金,No.2020JJ4932.
作者简介
黄之,硕士研究生,研究方向为肠道菌群在非酒精性脂肪性肝病发病中的作用;通讯作者:周蓉蓉,副教授,副主任医师,410000,湖南省长沙市湘雅路87号,中南大学湘雅医院感染病科病毒性肝炎湖南省重点实验室.rr-xy1234@csu.edu.cn。
